GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.

Conference Call Information:

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com

Source: Altimmune, Inc